ReviewThe British journal of surgery2018
Patient-derived organoid models help define personalized management of gastrointestinal cancer.
Review in The British journal of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach.Journal of gastrointestinal cancer · 2024Pooled it
- Organoids in the Clinic: A Systematic Review of Outcomes.Cells, tissues, organs · 2023Pooled it
- Organoids of liver diseases: From bench to bedside.World journal of gastroenterology · 2019Pooled it
- Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine.Journal of gastric cancer · 2026Review
- Towards functional precision medicine? Evidence standards of organoids as patient-specific models.History and philosophy of the life sciences · 2026Article
- Organoid models: applications and research advances in gastric cancer.Frontiers in oncology · 2026Review
- Constructing an ultrasound-assisted organoid model for tumor management.Discover oncology · 2025Review
- Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy.International journal of molecular sciences · 2025Review
- Unveiling radiobiological traits and therapeutic responses of BRAFJournal of experimental & clinical cancer research : CR · 2025Article
- VONet: A deep learning network for 3D reconstruction of organoid structures with a minimal number of confocal images.Patterns (New York, N.Y.) · 2024Article
- A comprehensive preanalytical protocol for fresh solid tumor biospecimens.Methods (San Diego, Calif.) · 2024Article
- Drug repurposing for cancer therapy.Signal transduction and targeted therapy · 2024Review
- The future of cancer therapy: exploring the potential of patient-derived organoids in drug development.Frontiers in cell and developmental biology · 2024Review
- Article
- Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges.British journal of cancer · 2023Review
- Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Article
- Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.Current oncology (Toronto, Ont.) · 2023Review
- Murine and Human Gastric Tissue Establishes Organoids after 48 Hours of Cold Ischemia Time during Shipment.Biomedicines · 2023Article
- Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.Frontiers in immunology · 2023Article
- 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.The Journal of clinical investigation · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe prognosis of patients with different gastrointestinal cancers varies widely. Despite advances in treatment strategies, such as extensive resections and the addition of new drugs to chemotherapy regimens, conventional treatment strategies have failed to improve survival for many tumours. Although promising, the clinical application of molecularly guided personalized treatment has proven to be challenging. This narrative review focuses on the personalization of cancer therapy using patient-derived three-dimensional 'organoid' models.
methodsA PubMed search was conducted to identify relevant articles. An overview of the literature and published protocols is presented, and the implications of these models for patients with cancer, surgeons and oncologists are explained.
resultsOrganoid culture methods have been established for healthy and diseased tissues from oesophagus, stomach, intestine, pancreas, bile duct and liver. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens, they can serve as a personal cancer model. Personalized treatment could become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient's tumour. However, the predictive capability of organoid drug screening has not been evaluated in prospective clinical trials.
conclusionHigh-throughput drug screening on organoids, combined with next-generation sequencing, proteomic analysis and other state-of-the-art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.